| Title |
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
|
|---|---|
| Published in |
BMC Cancer, December 2011
|
| DOI | 10.1186/1471-2407-11-515 |
| Pubmed ID | |
| Authors |
Sucheta Telang, Mary Ann Rasku, Amy L Clem, Karen Carter, Alden C Klarer, Wesley R Badger, Rebecca A Milam, Shesh N Rai, Jianmin Pan, Hana Gragg, Brian F Clem, Kelly M McMasters, Donald M Miller, Jason Chesney |
| Abstract |
We previously found that administration of an interleukin 2/diphtheria toxin conjugate (DAB/IL2; Denileukin Diftitox; ONTAK) to stage IV melanoma patients depleted CD4(+)CD25(HI)Foxp3(+) regulatory T cells and expanded melanoma-specific CD8(+) T cells. The goal of this study was to assess the clinical efficacy of DAB/IL2 in an expanded cohort of stage IV melanoma patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 61 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 16% |
| Other | 7 | 11% |
| Student > Master | 6 | 10% |
| Researcher | 6 | 10% |
| Student > Ph. D. Student | 6 | 10% |
| Other | 10 | 16% |
| Unknown | 16 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 21% |
| Biochemistry, Genetics and Molecular Biology | 11 | 18% |
| Immunology and Microbiology | 6 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Agricultural and Biological Sciences | 3 | 5% |
| Other | 6 | 10% |
| Unknown | 18 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2013.
All research outputs
#7,168,360
of 22,659,164 outputs
Outputs from BMC Cancer
#1,934
of 8,238 outputs
Outputs of similar age
#67,225
of 242,398 outputs
Outputs of similar age from BMC Cancer
#25
of 96 outputs
Altmetric has tracked 22,659,164 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 8,238 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,398 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.